Shailendra Patel, MD
Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1861444713
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,588 of the $4,172 with a category attached, or 86.0%. Rhythm Pharmaceuticals, Inc. accounts for 92.2% of it on its own, with 1 other manufacturer making up the rest.
Across 12 payments — averaging $347.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rhythm Pharmaceuticals, Inc.$4K
- Chiesi USA, Inc.$325
Across 20 payments — averaging $3204.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$31K
- Novartis$14K
- Sanofi US Services Inc.$10K
- Chiasma, Inc.$8K
- Amryt Pharma Holdings Ltd$2K
What the payments were for
- Speaking & faculty fees$3,58886%
- Travel & lodging$47511%
- Food & beverage$1103%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rhythm Pharmaceuticals, Inc. | 11 | $3,847 |
| Chiesi USA, Inc. | 1 | $325 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYALEPT$325
How this compares
$4,172 in reported general payments places this provider in the 70th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $54,150 |
| MounjaroTirzepatide | 45 | $51,082 |
| JardianceEmpagliflozin | 45 | $47,383 |
| TrulicityDulaglutide | 19 | $35,471 |
| Repatha SureclickEvolocumab | 29 | $21,753 |
| JanuviaSitagliptin Phosphate | 11 | $11,617 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $10,107 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,302 |
| Hydrocortisone | 109 | $4,515 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $4,109 |
| Novolog FlexpenInsulin Aspart | 16 | $3,453 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,337 |
| Levothyroxine Sodium | 226 | $2,323 |
| SynthroidLevothyroxine Sodium | 18 | $1,876 |
| Desmopressin Acetate | 11 | $1,587 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Cincinnati
- Nelson WattsCincinnati$346K
- Shawn PeavieCincinnati$201K
- Amanda DenneyCincinnati$183K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.